Published in Eur J Pharmacol on June 22, 1988
Pharmacological characterization of acetylcholine-stimulated [35S]-GTP gamma S binding mediated by human muscarinic m1-m4 receptors: antagonist studies. Br J Pharmacol (1993) 1.33
Characterization of the muscarinic receptor subtype mediating contractions of the guinea-pig uterus. Br J Pharmacol (1989) 1.01
Binding and functional properties of antimuscarinics of the hexocyclium/sila-hexocyclium and hexahydro-diphenidol/hexahydro-sila-diphenidol type to muscarinic receptor subtypes. Br J Pharmacol (1989) 0.87
Binding and functional properties of hexocyclium and sila-hexocyclium derivatives to muscarinic receptor subtypes. Br J Pharmacol (1994) 0.81
SR proteins and splicing control. Genes Dev (1996) 7.09
Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature (1988) 3.60
P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J (1998) 3.23
Phosphorylated RNA polymerase II stimulates pre-mRNA splicing. Genes Dev (1999) 3.00
Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther (1991) 2.55
PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol (1992) 2.43
PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol (1993) 1.69
[Structure-activity relationship of N-methyl-3-pyrroline and N-methyl-pyrrolidine-3-carboxylic acid]. Arzneimittelforschung (1971) 1.40
Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms. Naunyn Schmiedebergs Arch Pharmacol (1985) 1.36
[Structure-activity relationships of unsaturated esters of arecaidine and dihydroarecaidine]. Arzneimittelforschung (1973) 1.35
Selective antagonism by PPADS at P2X-purinoceptors in rabbit isolated blood vessels. Br J Pharmacol (1994) 1.27
Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric arterial bed: selective inhibition by PPADS of contractions mediated via P2x-purinoceptors. Br J Pharmacol (1994) 1.27
Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int (1997) 1.27
Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr (1982) 1.26
Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet (1981) 1.22
Fluorimetric determination of atenolol in plasma and urine by direct evaluation of thin-layer chromatograms. J Chromatogr (1979) 1.18
Investigation of the actions of PPADS, a novel P2x-purinoceptor antagonist, in the guinea-pig isolated vas deferens. Br J Pharmacol (1994) 1.18
Fluorimetric determination of oxprenolol in plasma by direct evaluation of thin-layer chromatograms. J Chromatogr (1979) 1.17
p-fluoro-hexahydro-sila-difenidol: the first M2 beta-selective muscarinic antagonist. Eur J Pharmacol (1988) 1.16
Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int (1999) 1.14
Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine. Eur J Pharmacol (1987) 1.13
Pharmacological characterization of the vascular muscarinic receptors mediating relaxation and contraction in rabbit aorta. J Pharmacol Exp Ther (1991) 1.12
The U1 small nuclear ribonucleoprotein/5' splice site interaction affects U2AF65 binding to the downstream 3' splice site. J Biol Chem (1995) 1.07
Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J Biol Chem (1994) 1.07
Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes. Eur J Pharmacol (1989) 1.01
Syntheses and properties of bioactive organo-silicon compounds. Top Curr Chem (1979) 1.00
Muscarinic receptors mediating acid secretion in isolated rat gastric parietal cells are of M3 type. Gastroenterology (1990) 1.00
Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res (1993) 0.99
Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrob Agents Chemother (1987) 0.99
Inhibitory action of PPADS on relaxant responses to adenine nucleotides or electrical field stimulation in guinea-pig taenia coli and rat duodenum. Br J Pharmacol (1995) 0.96
Presynaptic muscarinic receptors mediating inhibition of neurogenic contractions in rabbit vas deferens are of the ganglionic M1-type. Eur J Pharmacol (1988) 0.96
[On the microbiological conversion of N-containing substrates. 4. On the microbiological conversion of 5-hydroxyindole through Clavic eps purpurea, Cordyceps militaris and Aspergillus oryzae]. Arch Pharm Ber Dtsch Pharm Ges (1968) 0.95
Influence of ranitidine on plasma metoprolol and atenolol concentrations. Br Med J (Clin Res Ed) (1983) 0.95
Sila-substitution--a useful strategy for drug design? Endeavour (1986) 0.95
Cefodizime penetration into skin suction blister fluid following a single intravenous dose. Eur J Clin Pharmacol (1986) 0.95
The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects. Eur J Clin Pharmacol (2006) 0.95
Atenolol interaction with aspirin, allopurinol, and ampicillin. Clin Pharmacol Ther (1983) 0.94
Different binding affinities of NMDA receptor channel blockers in various brain regions--indication of NMDA receptor heterogeneity. Neuropharmacology (1995) 0.94
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Clin Pharmacol Ther (1999) 0.94
NF279: a novel potent and selective antagonist of P2X receptor-mediated responses. Eur J Pharmacol (1998) 0.94
Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol (1995) 0.94
Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol (1997) 0.93
Characterization of the prejunctional muscarinic receptors mediating inhibition of evoked release of endogenous noradrenaline in rabbit isolated vas deferens. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.93
Vasoconstrictor responses via P2X-receptors are selectively antagonized by NF023 in rabbit isolated aorta and saphenous artery. Br J Pharmacol (1997) 0.93
Expression of the adhesion molecules L1, N-CAM and J1/tenascin during development of the murine small intestine. Differentiation (1990) 0.93
Increase in magnesium plasma level after orally administered trimagnesium dicitrate. Eur J Clin Pharmacol (1996) 0.92
Methoctramine selectively blocks cardiac muscarinic M2 receptors in vivo. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.92
Characterization of muscarinic receptors mediating vasodilation in rat perfused kidney. Eur J Pharmacol (1993) 0.92
Human HT-29 colon carcinoma cells contain muscarinic M3 receptors coupled to phosphoinositide metabolism. Eur J Pharmacol (1989) 0.92
Limitation on the use of amiloride in early renal failure. Eur J Clin Pharmacol (1985) 0.92
Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol (2000) 0.91
Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling. Life Sci (1995) 0.91
[Fluorometric determination of propranolol and its metabolite n-desisopropylpropranolol in plasma and urine by direct meausrement of thin-layer chromatographic plates (author's transl]. J Chromatogr (1977) 0.91
[Fluorimetric determination of amiloride in human plasma using thin-layer chromatography]. J Chromatogr (1982) 0.91
In vitro antispasmodic compounds of the dry extract obtained from Hedera helix. Planta Med (1997) 0.91
Bioavailability study of two different verapamil formulations. Arch Pharm (Weinheim) (1992) 0.90
Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol (1999) 0.89
The novel pyridoxal-5'-phosphate derivative PPNDS potently antagonizes activation of P2X(1) receptors. Eur J Pharmacol (2000) 0.89
A comparison of the antimuscarinic effects of pirenzepine and N-methylatropine on ganglionic and vascular muscarinic receptors in the rat. Life Sci (1984) 0.89
Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch (1996) 0.89
Muscarinic receptor subtypes in rat pancreatic islets: binding and functional studies. Eur J Pharmacol (1990) 0.88
Human gastric mucosa expresses glandular M3 subtype of muscarinic receptors. Dig Dis Sci (1990) 0.88
Delayed elimination of triamterene and its active metabolite in chronic renal failure. Eur J Clin Pharmacol (1983) 0.88
Predictability of the covalent binding of acidic drugs in man. Life Sci (1993) 0.87
[Determination and comparison of the plasma and urine concentrations in men given tranylcypromine stereoisomers]. Arzneimittelforschung (1979) 0.87
Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol (1981) 0.87
Binding and functional properties of antimuscarinics of the hexocyclium/sila-hexocyclium and hexahydro-diphenidol/hexahydro-sila-diphenidol type to muscarinic receptor subtypes. Br J Pharmacol (1989) 0.87
Functional role of a cytoplasmic aromatic amino acid in muscarinic receptor-mediated activation of phospholipase C. J Biol Chem (1994) 0.87
Influence of ranitidine on plasma metoprolol concentrations. Br Med J (Clin Res Ed) (1983) 0.87
Human plasma and skin blister fluid levels of griseofulvin following a single oral dose. Eur J Clin Pharmacol (1985) 0.87
HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats. J Pharm Biomed Anal (1998) 0.86
New functionally selective muscarinic agonists. Life Sci (1993) 0.86
Different muscarine receptors mediate the prejunctional inhibition of [3H]-noradrenaline release in rat or guinea-pig iris and the contraction of the rabbit iris sphincter muscle. Naunyn Schmiedebergs Arch Pharmacol (1989) 0.85
Blue native PAGE as a useful method for the analysis of the assembly of distinct combinations of nicotinic acetylcholine receptor subunits. J Recept Signal Transduct Res (1999) 0.85
Ketoconazole concentrations in human skin blister fluid and plasma. Int J Clin Pharmacol Ther Toxicol (1984) 0.85
Does cantharides blister fluid provide access to the peripheral compartment? Eur J Clin Pharmacol (1982) 0.85
Pharmacokinetics of amiloride in renal and hepatic disease. Eur J Clin Pharmacol (1987) 0.85
Selective antagonists provide evidence that M1 muscarinic receptors may mediate carbachol-induced drinking in the rat. Eur J Pharmacol (1990) 0.84
Novel pharmacological profile of muscarinic receptors mediating contraction of the guinea-pig uterus. Naunyn Schmiedebergs Arch Pharmacol (1990) 0.84
The pharmacological assessment of RS 86 (2-ethyl-8-methyl-2,8-diazaspiro-[4,5]-decan-1,3-dion hydrobromide). A potent, specific muscarinic acetylcholine receptor agonist. Eur J Pharmacol (1986) 0.84
Stereoselectivity of the enantiomers of trihexyphenidyl and its methiodide at muscarinic receptor subtypes. Eur J Pharmacol (1988) 0.84